These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26380071)

  • 1. A new hypothesis on HIV cure.
    Hladik F
    F1000Res; 2015; 4():77. PubMed ID: 26380071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
    Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
    J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS?
    De Clercq E; Balzarini J
    Farmaco; 1995 Nov; 50(11):735-47. PubMed ID: 8593170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reverse transcriptase inhibitors, protease inhibitors].
    Tachikawa N
    Nihon Rinsho; 2012 Apr; 70(4):579-95. PubMed ID: 22568138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational reverse transcriptase inhibitors for the treatment of HIV.
    Cory TJ; Midde NM; Rao P; Kumar S
    Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
    Cihlar T; Ray AS
    Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.
    Hammer SM
    Top HIV Med; 2006; 14(4):140-3. PubMed ID: 17114828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
    Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
    Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simian-human immunodeficiency virus carrying the rt gene from Chinese CRF01_AE strain of HIV is sensitive to nucleoside reverse transcriptase inhibitors and has a highly genetic stability in vivo.
    Wang W; Yao N; Ju B; Dong Z; Cong Z; Jiang H; Qin C; Wei Q
    Microbes Infect; 2014 Jun; 16(6):461-71. PubMed ID: 24709063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
    Weiss J; Weis N; Ketabi-Kiyanvash N; Storch CH; Haefeli WE
    Eur J Pharmacol; 2008 Jan; 579(1-3):104-9. PubMed ID: 18037401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral drugs.
    De Clercq E
    Curr Opin Pharmacol; 2010 Oct; 10(5):507-15. PubMed ID: 20471318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.
    Whitcomb JM; Parkin NT; Chappey C; Hellmann NS; Petropoulos CJ
    J Infect Dis; 2003 Oct; 188(7):992-1000. PubMed ID: 14513419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
    Bolduc P; Roder N; Colgate E; Cheeseman SH
    FP Essent; 2016 Apr; 443():23-30. PubMed ID: 27092564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.